Scott A Holmes Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Scott A Holmes.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Scott A Holmes. Scott A Holmes is Chief Accounting Officer in AMAG PHARMACEUTICALS INC. ($AVM) and SVP, Chief Accounting Officer in AMAG PHARMACEUTICALS INC. ($AVM) and SVP, Finance and Treasurer in AMAG PHARMACEUTICALS INC. ($AVM) and Chief Financial Officer in KERYX BIOPHARMACEUTICALS INC ($KERX).
Latest Insider Trading Transactions of Scott A Holmes
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 13 2018 | KERX | KERYX BIOPHARMACEU ... | Holmes Scott A | Chief Financial Off ... | Option Exercise | D | 0.00 | 902,500 | 0 | 0 | |
| Dec 13 2018 | KERX | KERYX BIOPHARMACEU ... | Holmes Scott A | Chief Financial Off ... | Sell | D | 0.00 | 162,956 | 0 | 0 | 163 K to 0 (-100.00 %) |
| Nov 16 2018 | KERX | KERYX BIOPHARMACEU ... | Holmes Scott A | Chief Financial Off ... | Sell | S | 2.77 | 1,155 | 3,199 | 162,956 | 164.1 K to 163 K (-0.70 %) |
| Oct 30 2018 | KERX | KERYX BIOPHARMACEU ... | Holmes Scott A | Chief Financial Off ... | Sell | S | 3.07 | 1,254 | 3,850 | 164,111 | 165.4 K to 164.1 K (-0.76 %) |
| Aug 16 2018 | KERX | KERYX BIOPHARMACEU ... | Holmes Scott A | Chief Financial Off ... | Sell | S | 3.04 | 1,185 | 3,602 | 165,365 | 166.6 K to 165.4 K (-0.71 %) |
| Jul 31 2018 | KERX | KERYX BIOPHARMACEU ... | Holmes Scott A | Chief Financial Off ... | Sell | S | 3.86 | 2,354 | 9,086 | 166,550 | 168.9 K to 166.6 K (-1.39 %) |
| May 16 2018 | KERX | KERYX BIOPHARMACEU ... | Holmes Scott A | Chief Financial Off ... | Sell | S | 5.69 | 1,158 | 6,589 | 168,904 | 170.1 K to 168.9 K (-0.68 %) |
| May 16 2018 | KERX | KERYX BIOPHARMACEU ... | Holmes Scott A | Chief Financial Off ... | Sell | S | 5.69 | 1,158 | 6,589 | 168,904 | 170.1 K to 168.9 K (-0.68 %) |
| May 01 2018 | KERX | KERYX BIOPHARMACEU ... | Holmes Scott A | Chief Financial Off ... | Sell | S | 4.67 | 2,407 | 11,241 | 170,062 | 172.5 K to 170.1 K (-1.40 %) |
| Mar 22 2018 | KERX | KERYX BIOPHARMACEU ... | Holmes Scott A | Chief Financial Off ... | Option Exercise | A | 4.16 | 82,500 | 343,200 | 82,500 | |
| Mar 22 2018 | KERX | KERYX BIOPHARMACEU ... | Holmes Scott A | Chief Financial Off ... | Grant | A | 0.00 | 41,250 | 0 | 172,469 | 131.2 K to 172.5 K (+31.44 %) |
| Jan 31 2018 | KERX | KERYX BIOPHARMACEU ... | Holmes Scott A | Chief Financial Off ... | Sell | S | 4.81 | 2,830 | 13,612 | 136,870 | 139.7 K to 136.9 K (-2.03 %) |
| Oct 31 2017 | KERX | KERYX BIOPHARMACEU ... | Holmes Scott A | Chief Financial Off ... | Sell | S | 6.03 | 2,582 | 15,569 | 139,700 | 142.3 K to 139.7 K (-1.81 %) |
| Aug 01 2017 | KERX | KERYX BIOPHARMACEU ... | Holmes Scott A | Chief Financial Off ... | Sell | S | 7.14 | 1,445 | 10,317 | 142,282 | 143.7 K to 142.3 K (-1.01 %) |
| Jul 31 2017 | KERX | KERYX BIOPHARMACEU ... | Holmes Scott A | Chief Financial Off ... | Sell | S | 6.96 | 1,236 | 8,603 | 143,727 | 145 K to 143.7 K (-0.85 %) |
| Mar 15 2017 | KERX | KERYX BIOPHARMACEU ... | Holmes Scott A | Chief Financial Off ... | Option Exercise | A | 5.53 | 97,500 | 539,175 | 97,500 | |
| Mar 15 2017 | KERX | KERYX BIOPHARMACEU ... | Holmes Scott A | Chief Financial Off ... | Grant | A | 0.00 | 48,750 | 0 | 147,623 | 98.9 K to 147.6 K (+49.31 %) |
| Jan 31 2017 | KERX | KERYX BIOPHARMACEU ... | Holmes Scott A | Chief Financial Off ... | Sell | S | 4.65 | 8,447 | 39,279 | 98,873 | 107.3 K to 98.9 K (-7.87 %) |
| Oct 31 2016 | KERX | KERYX BIOPHARMACEU ... | Holmes Scott A | Chief Financial Off ... | Sell | S | 4.44 | 1,237 | 5,492 | 107,320 | 108.6 K to 107.3 K (-1.14 %) |
| Aug 02 2016 | KERX | KERYX BIOPHARMACEU ... | Holmes Scott A | Chief Financial Off ... | Sell | S | 7.36 | 4,935 | 36,322 | 108,557 | 113.5 K to 108.6 K (-4.35 %) |
| Feb 01 2016 | KERX | KERYX BIOPHARMACEU ... | Holmes Scott A | Chief Financial Off ... | Option Exercise | A | 3.35 | 107,500 | 360,125 | 107,500 | |
| Feb 01 2016 | KERX | KERYX BIOPHARMACEU ... | Holmes Scott A | Chief Financial Off ... | Grant | A | 0.00 | 53,750 | 0 | 113,492 | 59.7 K to 113.5 K (+89.97 %) |
| Nov 05 2015 | KERX | KERYX BIOPHARMACEU ... | Holmes Scott A | Chief Financial Off ... | Buy | P | 5.40 | 1,328 | 7,171 | 59,742 | 58.4 K to 59.7 K (+2.27 %) |
| Nov 05 2015 | KERX | KERYX BIOPHARMACEU ... | Holmes Scott A | Chief Financial Off ... | Buy | P | 5.30 | 3,672 | 19,458 | 58,414 | 54.7 K to 58.4 K (+6.71 %) |
| Aug 24 2015 | KERX | KERYX BIOPHARMACEU ... | Holmes Scott A | Chief Financial Off ... | Buy | P | 5.72 | 5,000 | 28,590 | 54,742 | 49.7 K to 54.7 K (+10.05 %) |
| Aug 03 2015 | KERX | KERYX BIOPHARMACEU ... | Holmes Scott A | Chief Financial Off ... | Sell | S | 7.87 | 2,758 | 21,705 | 49,742 | 52.5 K to 49.7 K (-5.25 %) |
| Jun 17 2015 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | SVP, Finance and Tr ... | Option Exercise | M | 16.55 | 3,500 | 57,925 | 11,500 | |
| Jun 17 2015 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | SVP, Finance and Tr ... | Option Exercise | M | 14.89 | 2,734 | 40,709 | 14,375 | |
| Jun 17 2015 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | SVP, Finance and Tr ... | Sell | S | 66.63 | 6,234 | 415,371 | 51,958 | 58.2 K to 52 K (-10.71 %) |
| Jun 17 2015 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | SVP, Finance and Tr ... | Buy | M | 16.55 | 3,500 | 57,925 | 58,192 | 54.7 K to 58.2 K (+6.40 %) |
| Jun 17 2015 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | SVP, Finance and Tr ... | Buy | M | 14.89 | 2,734 | 40,709 | 54,692 | 52 K to 54.7 K (+5.26 %) |
| Jun 17 2015 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | SVP, Finance and Tr ... | Sell | S | 66.63 | 1,346 | 89,684 | 51,958 | 53.3 K to 52 K (-2.53 %) |
| Jun 05 2015 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | SVP, Finance and Tr ... | Sell | S | 68.88 | 22,516 | 1,550,902 | 30,788 | 53.3 K to 30.8 K (-42.24 %) |
| Mar 05 2015 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | SVP, Chief Accounti ... | Payment of Exercise | F | 49.70 | 533 | 26,490 | 53,304 | 53.8 K to 53.3 K (-0.99 %) |
| Feb 27 2015 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | SVP, Chief Accounti ... | Option Exercise | A | 49.46 | 10,000 | 494,600 | 10,000 | |
| Feb 27 2015 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | SVP, Chief Accounti ... | Grant | A | 0.00 | 5,000 | 0 | 53,837 | 48.8 K to 53.8 K (+10.24 %) |
| Dec 06 2012 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | Chief Accounting Of ... | Option Exercise | M | 0.00 | 2,500 | 0 | 2,500 | |
| Dec 06 2012 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | Chief Accounting Of ... | Sell | S | 14.79 | 2,500 | 36,975 | 0 | 2.5 K to 0 (-100.00 %) |
| Dec 06 2012 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | Chief Accounting Of ... | Buy | M | 0.00 | 2,500 | 0 | 2,500 | 0 to 2.5 K |
| Sep 13 2012 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | Chief Accounting Of ... | Option Exercise | C | 0.00 | 750 | 0 | 750 | |
| Sep 13 2012 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | Chief Accounting Of ... | Sell | S | 15.54 | 750 | 11,655 | 0 | 750 to 0 (-100.00 %) |
| Sep 13 2012 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | Chief Accounting Of ... | Buy | C | 0.00 | 750 | 0 | 750 | 0 to 750 |
| Jun 27 2012 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | Chief Accounting Of ... | Option Exercise | A | 14.89 | 30,000 | 446,700 | 30,000 |
Page: 1